Back to top
more

Accelerate Diagnostics, Inc. (AXDX)

(Real Time Quote from BATS)

$14.95 USD

14.95
62,704

-0.65 (-4.17%)

Updated Aug 6, 2020 11:32 AM ET

3-Hold of 5     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.33%
17.77%
9.37%
4.88%
1.79%
10.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value D Growth F Momentum F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Moves to Strong Buy: Rationale Behind the Upgrade

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AXDX

Zacks Equity Research

How Accelerate Diagnostics (AXDX) Stock Stands Out in a Strong Industry

Accelerate Diagnostics (AXDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

AXDX

Zacks Equity Research

Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Moves to Buy: Rationale Behind the Upgrade

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.13% and -27.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

AXDX

Zacks Equity Research

Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Jumps: Stock Rises 9.4%

Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.00% and -33.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.98% and -17.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AXDX

Zacks Equity Research

Analysts Estimate Accelerate Diagnostics (AXDX) to Report a Decline in Earnings: What to Look Out for

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Earnings Preview: Accelerate Diagnostics (AXDX) Q4 Earnings Expected to Decline

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.82% and -53.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

AXDX

Zacks Equity Research

Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Surges: Stock Moves 6% Higher

Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

PEN AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -16.22% and -22.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

AXDX

Zacks Equity Research

Moving Average Crossover Alert: Accelerate Diagnostics, Inc. (AXDX)

Moving Average Crossover Alert: Accelerate Diagnostics, Inc. (AXDX)

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher

Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.

IDXX AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%

Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise more than 5% on the day.

AXDX EW

Zacks Equity Research

Here's Why You Can Buy Quest Diagnostics Stock Right Now

Quest Diagnostics Incorporated (DGX) is on a healthy growth trajectory of late.

INGN AXDX DGX ALGN

Zacks Equity Research

Illumina Offers FDA-Approved NGS Cancer Companion Test Kit

Illumina, Inc. (ILMN) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines.

INGN AXDX ILMN ALGN

Zacks Equity Research

Lantheus Holdings at 52-Week High: What's Driving the Stock?

Share price of Lantheus Holdings, Inc. (LNTH), based in North Billerica, U.S., scaled a new 52-week high of $17.85 on Jun 30, eventually closing a bit lower at $17.65.

INGN AXDX LNTH ALGN

Zacks Equity Research

Envision Healthcare (EVHC) Acquires Anesthesia Associates

Envision Healthcare Corporation (EVHC), recently announced that it has acquired Connecticut based anesthesia physician group practice, Anesthesia Associates of New London, P.C.

INGN AXDX ALGN

Zacks Equity Research

Boston Scientific Rides on New Growth Plans amid Headwinds

On Jun 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

INGN AXDX BSX ALGN